ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (“the Company” or “RegeneRx”) today announced that the following letter to stockholders will be posted today to the investor relations section of the Company’s web site at www.regenerx.com:
